$8.60 Million in Sales Expected for Intellia Therapeutics, Inc. (NASDAQ:NTLA) This Quarter

Wall Street analysts expect Intellia Therapeutics, Inc. (NASDAQ:NTLA) to announce sales of $8.60 million for the current quarter, Zacks reports. Eight analysts have issued estimates for Intellia Therapeutics’ earnings, with the highest sales estimate coming in at $15.22 million and the lowest estimate coming in at $4.67 million. Intellia Therapeutics reported sales of $22.22 million during the same quarter last year, which would suggest a negative year over year growth rate of 61.3%. The company is expected to announce its next earnings results on Thursday, November 4th.

According to Zacks, analysts expect that Intellia Therapeutics will report full-year sales of $32.43 million for the current financial year, with estimates ranging from $22.33 million to $49.99 million. For the next financial year, analysts expect that the business will report sales of $43.22 million, with estimates ranging from $22.80 million to $70.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.40). The firm had revenue of $6.55 million for the quarter, compared to analysts’ expectations of $12.21 million. Intellia Therapeutics had a negative net margin of 442.58% and a negative return on equity of 39.01%. The firm’s revenue was down 59.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.61) EPS.

NTLA has been the subject of a number of analyst reports. Roth Capital upped their price target on Intellia Therapeutics from $110.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 5th. Oppenheimer upped their price objective on Intellia Therapeutics from $125.00 to $160.00 and gave the stock a “market perform” rating in a research note on Friday, August 6th. Barclays increased their price target on Intellia Therapeutics from $88.00 to $134.00 and gave the company an “overweight” rating in a research note on Monday, June 28th. JMP Securities increased their price target on Intellia Therapeutics from $160.00 to $175.00 and gave the company a “market outperform” rating in a research note on Friday, August 6th. Finally, The Goldman Sachs Group upped their price objective on Intellia Therapeutics from $225.00 to $252.00 and gave the company a “buy” rating in a research report on Friday, August 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $143.38.

In other Intellia Therapeutics news, EVP Laura Sepp-Lorenzino sold 26,000 shares of the stock in a transaction on Wednesday, August 4th. The stock was sold at an average price of $138.24, for a total transaction of $3,594,240.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jean Francois Formela sold 553,376 shares of the stock in a transaction on Monday, June 28th. The shares were sold at an average price of $132.73, for a total value of $73,449,596.48. The disclosure for this sale can be found here. Insiders have sold a total of 833,279 shares of company stock worth $117,165,467 over the last 90 days. 3.90% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Intellia Therapeutics during the 2nd quarter worth about $3,928,000. Parametric Portfolio Associates LLC raised its stake in shares of Intellia Therapeutics by 139.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 65,872 shares of the company’s stock valued at $10,665,000 after buying an additional 38,365 shares during the last quarter. Comerica Bank purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $255,000. Marshall Wace LLP increased its stake in shares of Intellia Therapeutics by 401.3% in the 2nd quarter. Marshall Wace LLP now owns 74,744 shares of the company’s stock valued at $12,101,000 after purchasing an additional 59,835 shares in the last quarter. Finally, Mariner LLC purchased a new position in shares of Intellia Therapeutics in the 2nd quarter valued at about $2,426,000. 84.32% of the stock is owned by hedge funds and other institutional investors.

Shares of NTLA opened at $148.36 on Tuesday. The business has a 50-day simple moving average of $152.46 and a two-hundred day simple moving average of $106.68. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of -51.87 and a beta of 2.14. Intellia Therapeutics has a 52 week low of $18.81 and a 52 week high of $202.73.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

Featured Story: What are Institutional Investors?

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.